Sun Pharmaceutical Industries' Q4 results are anticipated to show organic growth, driven by gRevlimid sales. Key focus areas include sales growth and R&D guidance for FY26. Brokerages predict revenue and profit increases, with varying views on margin expansion and risks like tariffs and competition. Management commentary on new launches and acquisitions will be crucial.
